(NASDAQ: VOR) Vor Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.8%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.78%.
Vor Biopharma's earnings in 2026 is $627,779,000.On average, 10 Wall Street analysts forecast VOR's earnings for 2026 to be -$431,032,809, with the lowest VOR earnings forecast at -$459,773,852, and the highest VOR earnings forecast at -$405,646,269. On average, 10 Wall Street analysts forecast VOR's earnings for 2027 to be -$215,344,834, with the lowest VOR earnings forecast at -$320,334,241, and the highest VOR earnings forecast at -$172,759,815.
In 2028, VOR is forecast to generate -$234,412,841 in earnings, with the lowest earnings forecast at -$339,757,222 and the highest earnings forecast at -$162,134,267.